ASTRO 2017: Practice-Changing Abstracts in Prostate, Renal Cancers
This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.
In this video, Gerard Morton, MD, of Odette Cancer Centre in Canada, discusses selected studies on the treatment of genitourinary cancers presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.
Morton was the discussant for a session on genitourinary cancer that featured the following abstracts, which were selected for their importance in potentially changing practice:
• Abstract 1: A prospective phase ii trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiotherapy (NRG/RTOG0526): Initial report of late toxicity outcome
• Abstract 330: Individual patient data meta-analysis of SBRT kidney: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)
• Abstract 336: Five-year outcomes of a phase I dose escalation study using stereotactic body radiosurgery for patients with clinically localized prostate cancer
• Abstract 1089: The use of chemotherapy instead of radiation therapy does not reduce incidence of second cancers in survivors of early stage seminoma: A population based study from British Columbia
• Abstract 282: Extremely dose escalated radiotherapy improves cancer-specific survival compared with radical prostatectomy or conventionally dose-escalated radiotherapy in Gleason score 9-10 prostate adenocarcinoma: a multi-institutional analysis of 1,403 patients
![“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa69f69efca1ade2e100fbb9cdf798d49ea5a0f94-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.")
